AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

IDT Offers Preferred Pricing and Early Access to Complete Portfolio of Coronavirus Research Tools

January 28, 2020 GMT

CORALVILLE, Iowa--(BUSINESS WIRE)--Jan 28, 2020--

Integrated DNA Technologies (IDT), a leading comprehensive genomics solutions provider, announced that it is accepting pre-orders from the global public health and research communities for qPCR primers and probes designed to detect the novel coronavirus, 2019-nCoV, which had an outbreak in Wuhan, Hubei Province, China.

The United States Centers for Disease Control and Prevention (CDC) released a panel of probes and primers on Monday, January 27, 2020, designed for specific detection of the virus. IDT is accepting orders for the panel immediately and will begin shipments next week. The virus detection panels will be manufactured in IDT’s global suite of cleanrooms designed to prevent synthetic template contamination, and the panels will be formulated to meet CDC’s recommended primer-to-probe ratio. To accompany the detection panels, the company has confirmed ‘ready to deliver’ positive and negative controls for 2019-nCoV, which can be used to ensure the accuracy and reliability of test results.

IDT will also provide eBlocks™ and gBlocks™ gene fragments and synthetic genes at preferred pricing, with priority shipping to researchers pursuing rapid vaccine development or exploring therapeutic interventions for 2019-nCoV. To facilitate quick turnaround of orders, the company’s entire gene synthesis support team is standing by to assist with coronavirus projects.

Trey Martin, President of IDT commented, “Fighting emergent pathogens is among the most important efforts that researchers undertake. We’re thankful for all the researchers willing to suit up for these battles, and if we can make their progress faster or easier, we’re going to be there to help them.”

The company has opened a dedicated channel for inquiries relating to 2019-nCoV detection and vaccine development products. Researchers can email coronavirus@idtdna.com to pre-order, and for preferred pricing and priority shipping. IDT’s scientific application support team will address inquiries and guide customers through the process.

Follow IDT on Twitter @idtdna for real-time updates and insights.

About IDT

Integrated DNA Technologies, Inc. (IDT) develops, manufactures, and markets nucleic acid products for the life sciences industry in the areas of academic and commercial research, agriculture, medical diagnostics, and pharmaceutical development. IDT has developed proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. Through its GMP services, IDT manufactures products used by researchers in diagnostic tests for many forms of cancer and most inherited and infectious diseases. IDT is widely recognized as the industry leader in custom nucleic acid manufacture, serving over 130,000 life sciences researchers. IDT has its manufacturing headquarters in Coralville, Iowa, USA, with additional manufacturing sites in San Diego, California, USA; Leuven, Belgium; and Singapore.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200128005794/en/

CONTACT: Brian Werger

Manager of Public Relations

800-328-2661 (US & Canada)

+1 319-626-8400 (outside US)

idtpr@idtdna.com

www.idtdna.com

KEYWORD: IOWA CHINA UNITED STATES NORTH AMERICA ASIA PACIFIC

INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES OTHER SCIENCE RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Integrated DNA Technologies, Inc.

Copyright Business Wire 2020.

PUB: 01/28/2020 03:25 PM/DISC: 01/28/2020 03:25 PM

http://www.businesswire.com/news/home/20200128005794/en